BC Week In Review | Jul 16, 2012
Company News

Tactic Pharma, Wilson Therapeutics deal

Wilson acquired Decuprate ( ATN-224 ) from Tactic. Wilson plans to develop the copper-specific binder for Wilson's disease, a rare autosomal recessive disorder caused by mutation in the ATP7B gene, which leads to an inability to properly...
Items per page:
1 - 1 of 1